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Previous findings have demonstrated that variants in nicotinic receptor genes are associated with nicotine, al-
cohol andcocainedependence.Becauseof thesubstantial comorbidity, it hasoftenbeenunclearwhetheravari-
ant is associated with multiple substances or whether the association is actually with a single substance. To
investigate the possible contribution of rare variants to the development of substance dependencies other
than nicotine dependence, specifically alcohol and cocaine dependence, we undertook pooled sequencing of
the coding regions and flanking sequence of CHRNA5, CHRNA3, CHRNB4, CHRNA6 and CHRNB3 in 287
African American and 1028 European American individuals from the Collaborative Study of the Genetics of
Alcoholism (COGA). All members of families for whom any individual was sequenced (2504 African
Americans and 7318 European Americans) were then genotyped for all variants identified by sequencing. For
each gene, we then tested for association using FamSKAT. For European Americans, we find increased DSM-
IV cocaine dependence symptoms (FamSKAT P5 23 1024) and increased DSM-IV alcohol dependence symp-
toms (FamSKAT P 5 5 3 1024) among carriers of missense variants in CHRNB3. Additionally, one variant
(rs149775276; H329Y) shows association with both cocaine dependence symptoms (P 5 7.4 3 1025, b 5 2.04)
and alcohol dependence symptoms (P 5 2.6 3 1024, b 5 2.04). For African Americans, we find decreased co-
caine dependence symptoms among carriers of missense variants in CHRNA3 (FamSKAT P 5 0.005).
Replication in an independent sample supports the role of rare variants in CHRNB3 and alcohol dependence
(P5 0.006).Theseare thefirst results to implicate rarevariants inCHRNB3orCHRNA3 in risk foralcoholdepend-
ence or cocaine dependence.
INTRODUCTION
Twin and adoption studies have suggested that in addition to
genetic variants that contribute to the risk of becoming depend-
ent on a specific drug, there exist genetic factors underlying a
generalized risk for becoming dependent onmultiple substances
[ (1) for review, (2,3)]. Epidemiological studies have shownhigh
levels of comorbidity among alcohol, cocaine and nicotine
dependence (4,5). Because of the substantial comorbidity, it
is often unclear whether a variant is associated with multiple
substances or whether the association is actually with a single
substance but the extensive comorbidity leads to apparent
association with other substances. Numerous studies have
found that variants altering the function or expression of neuron-
al cholinergic nicotinic receptors (CHRNs) alter risk for becom-
ing nicotine dependent and several have shown effects of
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variants in nicotinic receptors on risk for both alcohol and
cocainedependence [ (6) for review].Commonsinglenucleotide
polymorphisms (SNPs) inCHRNA5 andCHRNB3 are associated
with nicotine dependence or cigarette consumption (7,8). The
most strongly associatedSNP inseveral genome-wide association
studies (GWAS) of nicotine dependence, a non-synonymous
change (rs16969968/D398N) in CHRNA5, has also been
shown tomitigate risk for cocaine dependence (9,10). Addition-
ally, a highly correlated group of variants near CHRNA5, previ-
ously shown to alter CHRNA5 mRNA expression in vivo, have
been reported to alter risk for alcohol dependence (11) in add-
ition to nicotine dependence (12). GWAS of cigarette consump-
tion has also implicated a group of common SNPs near the
CHRNB3-CHRNA6 gene cluster (13) that have been suggested
to be involved in alcohol consumption, although not with
cocaine-related behaviors (14).
In addition tomediating the effects of nicotine, neuronal nico-
tinic receptors have also been shown to alter the cellular and be-
havioral effects of alcohol and cocaine independently of nicotine
(15–37). Evidence from in vitro studies indicates altered re-
sponse to ethanol upon perturbation of nicotinic receptors in
neurons (18,29–31,38). Studies in rats have shown that partial
agonists of a4b2∗ or a3b4∗ nicotinic receptors affect alcohol
consumption in vivo (15,18–21,24–28). These resultswere con-
firmed and expanded using transgenic and knockout mice for
various nicotinic receptor genes (16,17,32–37). The physio-
logical and behavioral effects of cocaine are also dependent
on nicotinic receptors. Studies in mice, rats and non-human
primates have suggested that cocaine administration alters nico-
tinic receptor expressionand in sodoing leads to altered response
to cocaine (39–42). A recent human trial also found that the
a4b2 subunit partial agonist Varenicline reduced alcohol con-
sumption among smokers (43). Together these results suggest
that altered nicotinic receptor expression and function likely
has an effect on alcohol and cocaine consumption independent
of its effect on nicotine consumption. However, despite the
promising evidence of synergy and cross-substance influences,
the combined effects of discovered common variants have
explained only a small proportion of the variance (5%) in nico-
tine dependence and even less of the variance in alcohol or
cocaine dependence (44). Rare variants may explain much of
the unexplained heritability of these complex substance use
disorders.
As a class, rare variants constitute themajority of genetic vari-
ation. A recent survey of .4000 exomes from individuals of
European and African descent showed that as much as 86% of
coding variants have a frequency ,0.05% and that these rare
variants are four times as likely to be deleterious (45). Many
examples now exist of rare variants contributing to common
human diseases [(46) for review], both in genes previously
reported to cause Mendelian forms of disease and in genes har-
boring common SNP associations. (47–49). Several studies
have demonstrated associations between rare variation in nicoti-
nic receptor genes and nicotine dependence (50–52). An effi-
cient method of determining the full spectrum of genetic
variation in a region and thus the relative contribution of rare
genetic variation to a trait of interest is to sequence pools of
DNA from multiple individuals and to use statistical methods
to determinewhich sites are polymorphic and atwhat frequency.
We have employed this approach to determine the contribution
of rare non-synonymous variants in the CHRNA5, CHRNA3,
CHRNB4, CHRNA6 and CHRNB3 genes to alcohol and cocaine
dependence.
RESULTS
We sequenced the protein coding regions of the five human cho-
linergic nicotinic receptor subunit genes constituting the gene
clusters previously reported to harbor common variants asso-
ciatedwith nicotine dependence (CHRNA5-CHRNA3-CHRNB4
and CHRNA6-CHRNB3) in 287 unrelated African Americans
(147 DSM-IV alcohol-dependent cases and 140 controls) and
1028 unrelated European Americans (480 DSM-IV alcohol-
dependent cases and 548 controls) as part of the Collaborative
Study of the Genetics of Alcoholism (COGA). DNA pools
were sequenced on an Illumina GAIIx and analyzed using the
SPLINTER algorithm (53). In total, we validated 31 non-
synonymous variants (Fig. 1 and Table 1). Of these, all but
rs16969968 were rare (,5% MAF), 9 (29%) were novel and
15 (48%) were present in only one sequenced individual. We
only attempted to validate non-synonymous variants as these
are more likely to have a functional impact than non-coding or
synonymous coding changes. As the SPLINTER algorithm pro-
duces a P-value for the probability that a predicted variant is a
true positive, we also genotyped 19 variants below our cut-off
for significance in order to determine the positive predictive
value of the algorithm. Only 1 of these 19 variants was validated
while 31 of 40 variants predicted to be true positives were vali-
dated. All variants included as part of the amplified positive
control vector were found upon achieving greater .30-fold
coverage at mutated sites (Sensitivity ¼ 100%) and only 63
sites in the 1908 bp negative control vector were predicted to
be polymorphic (Specificity ¼ 97%).
We genotyped each missense variant validated from seq-
uencing in every individual from the COGA study for whom
DNA existed, totaling 2504 African Americans and 7318 Euro-
pean Americans. We then tested for association between non-
synonymous variant carrier status at each sequenced gene and
either alcohol or cocaine dependence symptom count using the
family-based Sequence Kernel Association Test (FamSKAT),
which incorporates relatedness into the model using a kinship
matrix. Age, sex and the number of cigarettes smoked per day
(CPD) were included in the model as covariates. To increase
the chances of novel findings, we did not include the SNP
rs16969968 in analyses of European Americans or African
Americans as it might overshadow the effects of other variants
in the CHRNA5 gene and because it is common in European
Americans (Frequency ¼ 0.35).
Analysis of European Americans
ForEuropeanAmericans,wefind increasedDSM-IValcohol de-
pendence symptoms (0.97+ 2.2 versus. 0.65+ 1.8, famSKAT
P ¼ 6 × 1024) as well as increased DSM-IV cocaine depend-
ence symptoms (2.37+ 2.6 versus. 2.07+ 2.4, famSKAT
P ¼ 4 × 1024) DSM-IV cocaine dependence symptoms
(2.37+ 2.6 versus. 2.07+ 2.4, famSKAT P ¼ 4 × 1024)
among carriers of missense variants in the CHRNB3-A6 gene
cluster. We observed increased DSM-IV alcohol dependence
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symptoms (1.3+ 2.5 versus. 0.65+ 1.8, famSKAT P ¼ 5 ×
1024) and increased DSM-IV cocaine dependence symptoms
(2.27+2.7 versus. 2.07+2.4, famSKAT P¼ 2× 1024) among
carriers of missense variants in CHRNB3 but not for variants
in CHRNA6 (Table 2, Table 3 and Fig. 2). Further, among the
SNPs comprising the CHRNB3 carrier genotype (S326T, H329Y,
K451E and V368M), one variant (rs149775276; H329Y) was sig-
nificantly associated in a linear regression model with increases
in both alcohol dependence symptoms (P ¼ 2.6× 102 each gene
for associationwithCPDusing famSKATand found no significant
associations between CPD and rare missense variants at any of the
genes sequenced in thisdata set, suggesting that this is adirect effect
of thesevariants on risk for alcohol andcocainedependencepheno-
types (Table 2).
To determine whether these findings were the result of a correl-
ation between alcohol or cocaine symptom count and smoking,
which had not been accounted for using CPD as a covariate, we
tested whether these associations remained when only heavy
smokers (CPD ≥20) were analyzed, as there is no significant cor-
relation between alcohol symptom count or cocaine symptom
count and CPD among these heavy smoking individuals. Using
only heavy smokers (n¼ 2509), the association between
CHRNB3 and alcohol symptom count (famSKAT P ¼ 0.0064)
and cocaine dependence symptom count (famSKAT P ¼ 0.002)
remained significant, although reduced. No associations between
carrier status at any sequenced gene and alcohol or cocaine
symptom count were observed in non-smokers (n ¼ 3177).
Despite large numbers of non-smokers, very few non-smokers
are alcohol dependent (n ¼ 387; 12%) or cocaine dependent
(n ¼ 73; 2%), greatly reducing power to detect associations
with these phenotypes in this subset of individuals. Overall,
these analyses suggest that rareCHRNB3 variants are associated
with cocaine dependence symptoms and alcohol dependence
symptoms and that these associations cannot be fully explained
by comorbid smoking behavior.
As expected, there are high rates of comorbidity between
cocaine dependence and alcohol dependence in our sample.
For example, only 3% of European cocaine-dependent cases
and 5% of African-Americans cocaine-dependent cases in
our sample have no symptoms of alcohol dependence. To deter-
mine whether the observed association in European Americans
between CHRNB3 variants and either cocaine dependence
symptoms or alcohol dependence symptoms could be explained
by a correlation between the two phenotypes, we included
alcohol dependence symptomcount as a covariate in the analysis
of cocaine dependence and vice versa. The association between
cocaine dependence symptoms and both CHRNB3 (famSKAT
P ¼ 0.009) and rs149775276 (linear regression P ¼ 0.002)
remained significant when alcohol dependence was used as a
covariate. Using cocaine dependence symptom count as a covari-
ate, however,CHRNB3 carrier status did not remain significantly
associated with alcohol dependence symptoms (famSKAT P ¼
0.66). These findings suggest that variants in CHRNB3 increase
risk for cocaine dependence, but only increase risk for alcohol de-
pendence indirectly by increasing risk for cocaine dependence
symptoms or that the structure of the data set is such that one
cannotcorrect for cocainedependence symptomswithout disrupt-
ing all associations with alcohol dependence symptoms.
Figure 1. Schematics of theCHRN genes studied and the locations of missense variants identified in sequenced individuals from the COGA study. Each protein con-
sists of a signal peptide, two extracellular domains, four transmembrane domains (TM1-4) and three intracellular domains. Conserved sites (phyloP44 Vertebrate
score .2) are shown in gray, while all others are shown in black.
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One group of common SNPs within the CHRNB3-CHRNA6
genecluster (tagged inourdata set by rs6474412)waspreviously
shown to affect levels of nicotine consumption (8,13). To deter-
mine whether our findings in CHRNB3 could be due to linkage
disequilibrium with this variant, we tested for association
between rs6474412 and both alcohol and cocaine dependence
symptom count, but in neither case was a significant association
observed (alcohol symptom count P ¼ 0.49, b ¼ 20.03;
cocaine symptom count: P ¼ 0.91, b ¼ 20.01). This suggests
that our observed associations are not due to a correlation
between rare variants in CHRNB3 and the previously described
common variant.
To ensure that our findings within the European American
portion of the COGA sample are not due to population stratifica-
tion, we calculated principal components using EIGENSTRAT
(54).We then tested for association betweenCHRNB3missense
variants and both alcohol and cocaine dependence symptom
count including the first two principal components (PC1 and
PC2) as covariates. CHRNB3 carrier status remained associated
with both alcohol dependence symptom count (famSKAT P ¼
5.6 × 1024) and cocaine dependence symptom count in Euro-
pean Americans (famSKAT P ¼ 2.3 × 1024). These findings
suggest that the observed association is not due to population
stratification.
Analysis of African Americans
For African Americans, we found decreased DSM-IV cocaine
dependence symptoms (famSKAT P ¼ 0.01) and decreased
DSM-IV alcohol dependence symptoms (famSKAT P ¼ 0.05)
among carriers of missense variants in the CHRNA5-B4-A3
gene cluster. This association was driven by decreased DSM-IV
cocaine dependence symptoms (famSKAT P ¼ 0.005) and
decreased DSM-IV alcohol dependence symptoms (famSKAT
P ¼ 0.02) among carriers of missense variants in CHRNA3
(Tables 2 and 3). As for European Americans, age, sex and
CPD were included as covariates in the analysis. As there were
only two missense variants observed in CHRNA3 in African
Americans, this association was due largely to the associat-
ion between cocaine dependence symptoms and one variant
(rs8192475; R37H). This variant was previously shown to de-
crease risk for nicotine dependence and increase cellular response
tonicotine in vitro (52).The associationbetweenCHRNA3carrier
status and cocaine dependence symptom count remained sig-
nificant even after alcohol dependence symptoms was included
as a covariate (famSKAT P ¼ 0.04).
To determine whether our findings in African Americans
could be explained by subtle population stratification, we calcu-
lated principal components using EIGENSTRAT (54) and
Table 1. Characteristics and frequencies of variants observed in the COGA data set
Gene Amino
acid
position
CHR hg19
position
A1 A2 PhyloP
score
SIFT Polyphen Frequency in
COGA EAs
Frequency in
COGA AAs
Frequency in
COGEND EAs
Frequency in
COGEND AAs
CHRNB3 L250P 8 42587199 C T 5.117 + ++ 0.0021 0 0 0
CHRNB3 S326T 8 42587426 T A 0.672 + 0 0.0028 0 0.0022
CHRNB3 H329Y 8 42587435 C T 3.982 + ++ 0.0019 0.0120 0.0020 0
CHRNB3 V368M 8 42587552 A G 4.767 0.0188 0 0 0
CHRNB3 K451E 8 42591735 G A 2.350 0.0096 0.0423 0.0007 0.0515
CHRNA6 N447S 8 42611002 T C 3.502 + ++ 0.0007 0 0 0.0006
CHRNA6 K408E 8 42611120 C T 3.527 0.0028 0 0 0
CHRNA6 V314G 8 42611401 C A 7.129 + ++ 0.0087 0.0005 0 0
CHRNA6 I226T 8 42611665 C T 5.214 + 0.0069 0 0 0
CHRNA6 V110I 8 42612117 C T 2.128 0.0035 0 0 0
CHRNA6 R96H 8 42612158 C T 0.939 + + 0.0007 0.0002 0 0.0010
CHRNA6 S43P 8 42620300 A G 1.234 + 0.0034 0.0110 0.0003 0.0145
CHRNA5 F76V 15 78873272 T G 4.712 ++ 0.0021 0 0 0
CHRNA5 V134I 15 78880752 A G 6.721 + ++ 0.0175 0.0042 0.0147 0.0011
CHRNA5 K167R 15 78882233 A G 5.403 + ++ 0.0007 0.0158 0.0003 0.0157
CHRNA5 L317V 15 78882682 G C 2.262 + ++ 0.0038 0.0014 0 0
CHRNA5 L363Q 15 78882821 T A 4.767 + + 0.0034 0.0433 0.0005 0.0576
CHRNA5 D398N 15 78882925 A G 3.766 0.2920 0.0520 0.3494 0.0478
CHRNA3 E363D 15 78893895 G C 3.285 0.0042 0 0 0
CHRNA3 R37H 15 78911230 C T 2.671 + ++ 0.0458 0.0116 0.0521 0.0088
CHRNB4 M467V 15 78917573 T C 1.584 0.0192 0.0637 0 0.0759
CHRNB4 A435V 15 78921343 A G 20.549 + ++ 0.0145 0.0007 0 0
CHRNB4 A435T 15 78921344 T C 3.053 + + 0 0.0011 0 0
CHRNB4 R421X 15 78921386 A G 1.653 + + 0.0014 0 0 0
CHRNB4 T375I 15 78921523 G A 2.262 + 0 0.0168 0 0.0169
CHRNB4 R349C 15 78921602 A G 1.960 + ++ 0.0842 0.0030 0.0072 0.0006
CHRNB4 V311I 15 78921716 T C 2.402 + 0.0062 0 0 0
CHRNB4 S140G 15 78922229 C T 2.269 + 0.0555 0.0410 0.0040 0.0434
CHRNB4 R136Q 15 78922240 C T 0.410 0.1243 0.0024 0.0114 0.0016
CHRNB4 T91I 15 78923505 A G 2.161 0.3911 0.0074 0.0457 0.0067
CHRNB4 R18C 15 78933424 A G 5.625 0.0014 0 0 0
For SIFT predictions, variants predicted to be damaging are depicted with +. For polyphen predictions, variants predicted to be ‘possibly damaging’ are depicted
with + and variants predicted to be ‘probably damaging’ are depicted with ++.
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included the first two principal components (PC1 and PC2) as
covariates in the linear regression. CHRNA3 carrier status re-
mained associated with cocaine dependence symptom count in
African Americans (famSKAT P ¼ 0.01). No sequenced gene
other than CHRNA3 was significant before or after addition of
the first two principal components as covariates in the analysis.
Additionally, we calculated local admixture using LAMP (55).
CHRNA3 carrier status remained significantly associated with
Table 2. Collapsed frequencies and famSKAT results for each sequenced gene, sequenced gene cluster or all genes combined
European Americans African Americans
cMAF Alcohol P-value Cocaine P-value Nicotine P-value cMAF Alcohol P-value Cocaine P-value Nicotine P-value
CHRNA5 0.0037 0.764 0.696 0.868 0.0130 0.405 0.405 0.219
CHRNA6 0.0003 0.265 0.937 0.762 0.0017 0.510 0.646 0.295
CHRNB3 0.0010 5.5 × 1024 2.4 × 1024 0.202 0.0125 0.604 0.754 0.565
CHRNB4 0.0065 0.265 0.376 0.820 0.0133 0.087 0.065 0.898
CHRNA3 0.0234 0.417 0.360 0.854 0.0077 0.021 0.005 0.566
CHRNA5-A3-B4 0.0076 0.437 0.521 0.493 0.0128 0.05 0.014 0.684
CHRNB3-A6 0.0006 5.9 × 1024 4.0 × 1024 0.396 0.0063 0.734 0.734 0.499
All 0.0047 0.121 0.138 0.496 0.0101 0.122 0.047 0.721
For alcohol, DSMIV alcohol dependence symptom count was used as the phenotype and age, sex and CPD were used as covariates. For cocaine, DSMIV cocaine
dependence symptom count was used as the phenotype and age, sex and CPDwere used as covariates. For nicotine, CPDwas used as the phenotype and age and sex
were used as covariates.
Table 3. Demographic and phenotypic characteristics of COGA and COGEND African American and European American samples
CHRNB3 CHRNA3
Non-carriers Carriers P-value Non-carriers Carriers P-value
COGA European Americans
No. of individuals 4124 44 – 3765 398 –
Age (years) 37+16 37+15 0.95 39+15 40+15 0.37
Women/men 2076/2048 25/19 0.51 1878/1887 185/213 0.21
Cigarettes per day 21+13 19+12 0.6 20+13 20+13 0.86
Alcohol-dependent cases–controls 1796/2328 22/22 0.01 1634/2128 177/221 0.71
Alcohol symptom count 2.07+2.4 2.27+2.7 5.6 × 1024 2.9+2.51 3.04+2.48 0.28
Cocaine-dependent cases–controls 677/3447 12/32 0.005 601/3158 77/320 0.1
Cocaine symptom count 0.65+1.8 1.3+2.5 2.4 × 1024 1.03+2.21 1.16+2.3 0.26
COGA African Americans
No. of individuals 1121 143 – 1237 27 –
Age (years) 36+13 37+13 0.34 36+12 33+11 0.19
Women/men 503/618 64/79 1 558/679 9/18 0.24
Cigarettes per day 14+11 14+10 0.82 14+10 16+11 0.25
Alcohol-dependent cases–controls 530/590 74/69 0.32 595/641 9/18 0.17
Alcohol symptom count 2.99+2.51 3.32+2.56 0.13 3.04+2.52 2.66+2.18 0.445
Cocaine-dependent cases–controls 344/768 51/92 0.25 388/840 7/20 0.67
Cocaine symptom count 2.02+2.91 2.30+3.02 0.29 1.14+2.4 0.81+1.8 0.006
COGEND European Americans
No. of individuals 2036 11 – 1869 178 –
Age (years) 36+5 36+5 0.96 37+5 36+6 0.14
Women/men 1247/789 41489 0.54 1142/727 113/65 0.57
Cigarettes per day 18+17 18+19 0.99 19+17 17+17 0.14
Alcohol-dependent cases–controls 464/1530 4/7 0.3 434/1395 34/142 0.22
Alcohol symptom count 1.72+1.66 1.81+1.72 0.852 1.74+1.67 1.50+1.55 0.06
Cocaine-dependent cases–controls 131/1905 1/10 0.52 126/1743 6/172 0.11
Cocaine symptom count 0.43+1.44 0.55+1.81 0.8 0.45+1.48 0.26+1.12 0.08
COGEND African Americans
No. of individuals 641 69 – 700 10 –
Age (years) 37+6 33+5 0.93 37+5 38+6 0.14
Women/men 408/233 41/28 0.55 1142/727 113/65 0.57
Cigarettes per day 16+13 16+12 0.63 16+13 12+10 0.26
Alcohol-dependent cases–controls 66/575 13/56 0.06 78/622 1/9 1
Alcohol symptom count 1.35+1.72 2.00+2.34 0.004 1.43+1.80 1.43+2.6 0.99
Cocaine-dependent cases–controls 43/598 6/63 0.46 49/651 0/10 1
Cocaine symptom count 0.71+1.93 0.79+2.10 0.77 0.42+1.54 0+0 0.39
CPD,age, alcohol symptomcount andcocaine symptomcountvalues aremean+SD.P-values for sexandagewerecalculatedwith aFisher’s exact test andWilcoxon
Rank-Sum test, respectively. In COGA, P-values for primary phenotypes were calculated using FamSKAT in R using a kinship matrix with age, sex and CPD as
covariates. In COGEND, P-values for primary phenotypes were calculated using a Wilcoxon Rank-Sum test.
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cocaine dependence symptoms when we performed linear re-
gression including local admixture estimates from the 100 kb
encompassing the CHRNA5-CHRNA3-CHRNB4 gene cluster
as a covariate (famSKAT P ¼ 0.03). No sequenced gene other
than CHRNA3 was significant before or after addition of esti-
mated local ancestry as a covariate in the analysis. Thesefindings
suggest that the observed association is not due to population
stratification, either on a genome or a local scale.
Replication in COGEND
Previous findings from theCollaborativeGenetic Study ofNico-
tine Dependence (COGEND) have suggested that rare variants
inCHRNB4 reduce risk of nicotine dependence (52). Using pre-
viously obtained sequencing data from COGEND (51), we
aimed to determine whether we could replicate the findings
fromCOGA.We tested for association between alcohol depend-
ence symptom count and cocaine dependence symptom count
and variants in the CHRNB3 and CHRNA3 genes in the COGEND
sample as these genes were associated with these phenotypes
here in the COGA data set. We used both linear regression and
a non-parametric Wilcoxon Rank-Sum test as appropriate for
this sample of unrelated subjects. Linear regression using age,
sex, PC1, PC2 and CPD as covariates revealed that, among
African Americans, variants in CHRNB3 are associated with
increased alcohol dependence symptom count (P ¼ 0.0038, b ¼
0.48). This was then confirmed using a Wilcoxon Rank-Sum test
comparing the distribution of age, sex, PC1, PC2 and CPD
corrected alcohol symptomcount inCHRNB3 carriers versus non-
carriers (P ¼ 0.005). There was no association between either
alcohol or cocaine symptom count and CHRNA3 variants among
African Americans in the COGEND sample. More than 60%
(n ¼ 1685) of individuals in the COGEND sample have ≥1
alcohol dependence symptom, but there is a severe lack of power
to interrogate cocaine dependence symptoms in COGEND
because only 10% (n ¼ 290) of individuals in this data set
have non-zero cocaine dependence symptoms.
DISCUSSION
We find that rare missense variants in CHRNB3 are associated
with increased risk for cocaine dependence and alcohol depend-
ence amongEuropeanAmericans and that raremissense variants
in CHRNA3 are associated with decreased risk of cocaine de-
pendence among African Americans. Having tested five genes
and two primary phenotypes, alcohol and cocaine dependence
symptom count, the association between CHRNB3 variants
and both alcohol and cocaine dependence symptom count
amongEuropeanAmericans in theCOGAdata set are significant
after multiple test correction for 10 tests (P , 0.005) and the as-
sociation between CHRNA3 variants and cocaine dependence
symptom count among African Americans in COGA nearly
passes that significance threshold (P ¼ 0.005). We note that
the two primary phenotypes are correlated in the COGA data
set (EA r2 ¼ 0.22; AA r2 ¼ 0.36) and thus do not represent
two fully independent tests. These 10 tests of association were
performed in both European Americans and African Americans
within the COGA sample. The observed associations in COGA
were then tested for association in theCOGENDdata set for rep-
lication. We were able to observe an association between
CHRNB3 variants and alcohol dependence in the African-
American portion of COGEND but were unable to replicate
the association between CHRNA3 variants and either cocaine
or alcohol dependence symptom count in COGEND.
One possible explanation for the observed association bet-
ween rare variants in these genes and both alcohol and cocaine
dependence symptom count is the high rate of comorbidity for
these traits in the COGA sample. We attempted to determine
which of these two phenotypes was driving the associations
by including each as a covariate when analyzing the other. Our
findings suggest that the observed association with cocaine de-
pendence symptom count is not due to correlations between co-
morbid phenotypes, either alcohol or smoking, but that the
association between variants in CHRNB3 and alcohol depend-
ence symptoms among European Americans may reflect the
correlation of this trait with cocaine dependence symptoms in
the COGA data set. We find no evidence that the observed asso-
ciations are due to co-morbidity with smoking as we observe no
association between rare variants in these genes with CPD and
including CPD as a covariate in the analyses did not alter the
results.
TheassociationbetweenCHRNB3andbothalcoholandcocaine
dependencewas largelydue toonevariant (rs149775276;H329Y).
Thisvariantwas rare inEuropeanAmericans,butabsent inAfrican
Americans, partially explaining the lack of association at this
gene among African Americans in the COGA data set. We
were able to replicate the association between CHRNB3 and
Figure 2. Proportion of individuals among cocaine symptom counts in carriers
and non-carriers of (A) any CHRNB3 variant or (B) CHRNB3 H329Y.
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alcohol dependence in theCOGENDAfrican-American sample.
It is likely that we were able to observe an association between
CHRNB3 variants and alcohol dependence symptoms but not
cocaine dependence symptoms in COGEND because alcohol
dependence symptoms appear more often among COGEND
individuals (60%) than do cocaine dependence symptoms
(10%). Additionally, this association was only observed
among African-Americans individuals in COGEND. The fre-
quency ofCHRNB3 carriers among COGENDEuropean Amer-
icans was exceedingly small (0.6% of individuals) compared
with CHRNB3 carriers among African Americans (4%).
The association between CHRNA3 and cocaine dependence
among African Americans was due almost entirely to the
effect of one variant (R37H; rs8192475). This variant was previ-
ously shown to decrease risk for nicotine dependence and in-
crease cellular response to nicotine in vitro (52). Because
CHRNA3 R37H is rarer in African Americans (0.1%) than
European Americans (4%), the absence of association among
European Americans is not likely to be due to lack of power.
However, there may be an effect of differing genetic background
between the two ethnic groups that cannot be accounted for in our
analyses. Additionally, controlling for both global and local ad-
mixture in the African-American cohort does not affect the asso-
ciation observed between CHRNA3 and cocaine dependence
symptom counts, suggesting that this association is not due to
population stratification, however subtle.
For theothergenesstudied(CHRNB4,CHRNA6andCHRNA5),
no associations were observed between rare variants and
either alcohol or cocaine dependence in European Americans
or African Americans in COGA. This may have been due to in-
sufficient power resulting from low minor allele frequencies
even after collapsing genotypes within genes. Analysis of all
variants within each gene cluster (CHRNB3-A6 and CHRNA5-
A3-B4) revealed that each cluster was associated only when
one of the constituent genes was significantly associated by
itself. This suggests that the observed associations, between
rare variants across gene clusters, are merely a reflection of the
single-gene associations reported here.
There are several limitations to this study. First, we were not
able to fully account for the possible confounding of nicotine de-
pendence on the observed associations. We included CPD as a
covariate in our analyses, but ideallywewould perform the asso-
ciation in never-smokers or use FagerstromTest of Nicotine De-
pendence (FTND) score as a covariate. Unfortunately, very few
non-smokers are alcohol dependent (n ¼ 387; 12%) or cocaine
dependent (n ¼ 73; 2%) and FTND score had not been assessed
in much of the COGA data set and therefore could not be
included as a covariate in the analyses. Another limitation is
the lack of a comparable replication data set. The COGEND
data set was assessed for both alcohol and cocaine dependence
phenotypes, but lacks power due to limited sample size and
limited numbers of cocaine-dependent cases. Furthermore, the
COGEND sample is a case–control series, whereas COGA
sample includes extended families. If a rare variant is detected
in family, we were able to examine segregation with drug de-
pendence phenotypes in the rest of the family, which is not pos-
sible in a case–control series. Lastly, rare variant associations
aremore dependent on chance observation, namely the sampling
of rare allele carriers from a population, than studies of common
genetic variants. It is possible that our observed associationsmay
be due to chance fluctuations in rare variant alleles.
There is a debate in the scientific community regarding the
relative role of common versus rare genetic variants in determin-
ing an individual’s risk of developing common diseases.
Whether or not the majority of variability in any given trait
will eventually be attributed to common or rare variants is yet
to be determined. However, this and other studies continue to
demonstrate the power of rare variant association testing in the
identification and validation of genes contributing to common
disease. Moreover, rare variant associations have the ability to
identify specific genes and variants, rather than large genomic
regions. This suggests that in the era of whole-genome sequen-
cing, genome-wide gene-based rare variant associations may
be more powerful in identifying novel susceptibility loci. We
were not able to replicate our previously reported association
between rare missense variants in CHRNB4 and nicotine de-
pendence in the COGA cohort. One explanation for this is that
the COGA sample is not well suited for analysis of smoking-
related traits. The sample is a family data set ascertained to
study alcohol dependence and as such does not have the same
power as the COGEND sample to investigate smoking-related
traits. Secondly, not all of the subjects in the COGA sample
have been assessed for nicotine dependence.
In conclusion, we find an association between missense var-
iants inCHRNB3 andCHRNA3 and alcohol and cocaine depend-
ence symptom counts. Variants in CHRNB3 are associated with
increased risk for cocaine dependence and alcohol dependence,
while variants inCHRNA3 are associatedwith decreased risk for
cocaine dependence. Both CHRNB3 and CHRNA3 are asso-
ciatedwith cocainedependence independently of smokingquan-
tity as measured by CPD, a fact that is not surprising given the
role of CHRN genes in the physiological response to multiple
substances and the comorbidity of nicotine with both alcohol
and cocaine use in human populations. We hypothesize that
these variants act either by altering generalized reward path-
ways, by impacting impulsivity and related personality charac-
teristics or by altering the effect of alcohol or cocaine on
nicotinic receptors directly. Further sequencing of individuals
for whom detailed dependence-related information has been
obtained is necessary to confirm and elaborate on these findings
and functional studies will be necessary to elucidate the role of
these genes on the physiological effects of cocaine.
MATERIALS ANDMETHODS
COGA sample
DNA samples were collected as part of the COGA.All members
of theCOGAsample underwent a semi-structured interview, the
SSAGA, which assessed alcohol, cocaine and nicotine use as
well as comorbid psychiatric conditions. TheCOGA sample uti-
lized in this study consisted of 2504AfricanAmericans and7318
European Americans. Maximum lifetime CPD was used as a
covariate in all analyses. CPD was calculated by comparing
reports acrossmultiple interviews for an individual and selecting
thevalueofCPDthat reflected the largest number smokedduring
the time when the subject was smoking the most. Only in-
dividuals who had at one point in their life smoked have CPD
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values. Controls consisted of individuals who had tried a sub-
stance but never became dependent. A total of 287 African
American (147 cases and 140 controls) and 1028 European
American (480 cases and 548 controls) individuals were
sequenced. For African Americans, pools ranging in size from
44 to 96 individuals were used (two case pools and two control
pools). For European Americans, pools ranging in size from 68
to 96 individuals were used (five case pools and six control
pools). Follow-up genotyping of SNPs identified and validated
in the sequenced individuals was done in the remaining members
of each family represented in the sequenced set of individuals
(2217 African Americans and 6290 European Americans).
COGEND sample
DNA samples were collected as part of the CollaborativeGenetic
Study of Nicotine Dependence (COGEND). All members of the
COGENDsampleunderwent a semi-structured interview,which
assessed smoking behavior, other substance use and comorbid
psychiatric conditions. The COGEND sample includes 710
African Americans and 2055 European Americans. The coding
regions of the CHRNA3, CHRNB4, CHRNA5, CHRNB3 and
CHRNA6 genes were sequenced in a total of 352 African Amer-
icans (176 ND cases and 176 smoking controls) and 400 Euro-
pean Americans (200 ND cases and 200 smoking controls)
(51). Of these sequenced individuals, 120 (34%) of the African
Americans hadnon-zeroDSM-IValcohol dependence symptom
counts, 300 (75%) of the European Americans had non-zero
DSM-IV alcohol dependence symptom counts, 23 (6.5%) of
the African Americans had non-zero DSM-IV cocaine depend-
ence symptomcounts and 50 (12.5%) of the EuropeanAmericans
had non-zero DSM-IV cocaine dependence symptom counts. All
missense variants observed in these sequenced genes were geno-
typed in all members of COGEND using Sequenom.
Pooled sequencing
PooledDNAsequencingwas performed as previously described
(52,56). The concentrations of individual DNA samples were
first measured using Quant-iTTM PicoGreen reagent and
pooled in equimolar amounts. Each pooled DNA sample was
then used as the template for the amplification of each protein
coding exon of the CHRNA3, CHRNA5, CHRNA6, CHRNB3
and CHRNB4 genes. Primers for the amplification of each
exon were designed using Primer3 and reference sequences
were taken from the human genome reference assembly build
37 (hg19). To ensure complete coverage of each desired exon,
a minimum of 50 bp of a flanking sequence on each side was
required for eachamplicon.WeusedPfuhighfidelityDNApoly-
merase in all PCR reactions to reduce the identification of SNPs
generated as a result of the PCR (false-positive SNPs). After
PCR amplification of desired genomic regions, PCR products
were cleaned using QIAquick PCR purification kits, quantified
using Quant-iT PicoGreen reagent and ligated in equimolar
amounts using T4 Ligase and T4 Polynucleotide Kinase. At
this stage, positive and negative control vectors were amplified
and added to each pool to serve as internal quality standards
and to be used in data analysis. After ligation, concatenated
PCR products were randomly sheared by sonication and pre-
pared for Illumina sequencing on an Illumina GenomeAnalyzer
IIx (GAIIx) according to the manufacturer’s specifications. As
previously shown by Vallania et al. (53) an average coverage
of 30-fold per allele per pool was shown to correlate to optimal
positive predictive value for the SNP-calling algorithm and
was, therefore, the target level of coverage in this study.
Sequencing analysis
For analysis, sequencing reads (36 bp reads) were aligned using
an alignment algorithm developed by Vallania et al. (53) which
aligns sequences allowing for two mismatches or indels of up to
4 bp. To quantify the specificity and sensitivity of this method,
positive and negative control DNAwere introduced as PCR pro-
ducts in the pooled sequencing protocol outlined above. As a
positive control to estimate sensitivity for variant calling, a
pool of 10 plasmids with a 72 bp insert was generated. One
plasmid acts as the ‘wild-type’ insert, while the remaining nine
plasmids contain one or two synthetically engineeredmutations.
All 10 plasmids were combined such that each the allele fre-
quency of each known mutation would mimic either the allele
frequency of a single allelic variant or 10 allelic variants in our
humanDNA pool. Followingmixing of the vectors, PCR ampli-
fication across the insert sequence was performed and the PCR
product was added to the normalized pool of human target
PCR reactions during sequencing library preparation. We then
obtained more coverage for each amplicon than that which
was required to detect all variants in this amplified positive
control vector pool in order to ensure a minimal SNP detection
false-negative rate. As a negative control and to model the se-
quencing error rate, 1908 bp of the pCMV6-XL5 plasmid was
also amplified and included. One half of the pCMV6-XL5
plasmid sequence was used to train the SNP finding algorithm
and the other to test the error model. Finally, to identify variants,
in the pooled sequence data we used the SPLINTER algorithm
(53). TheSPLINTERalgorithmproduces aP-value for the prob-
ability that a predicted variant is a true positive. This probability
is produced using large deviation theory to quantify the differ-
ence between observed allele frequencies within the sequence
data to the background error rate for the same type of sequence
changes seen in the amplified pCMV6-XL5 plasmid. A P-value
cut-off value for each lane of Illumina sequencing was defined
as the value at which all positive controls were identified. Only
those variants falling below this cut-off value were considered
‘predicted’ by SPLINTER. All protein coding or splice site var-
iants predicted by SPLINTER were then validated by individual
Sequenom genotyping in each person from the source DNA
pools.SNPsvalidated in the sequenced individualswere thengen-
otyped in all members of the COGA sample. All individual geno-
typing was performed using the Sequenom platform as described
previously (11).
Association analysis
Single missense variants were tested for association in African
Americans and European Americans from the COGA study
using linear regression as implemented in the GWAF package
in R using age, sex and CPD as covariates. Each sequenced gene
was tested as a whole for association using famSKAT using
age, sex and CPD as covariates. The GWAF and famSKAT pro-
gramswereusedas theCOGAstudy is family-based and requires
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programs that can integrate family information. Associations in
COGEND between alcohol dependence symptom count or
cocaine dependence symptom count and variants in the
CHRNB3 or CHRNA3 genes were performed using linear regres-
sion inPLINKusing age, sex andCPDas covariates and inR com-
paring the residuals of alcohol or cocaine dependence symptom
count after correcting for age, sex and CPD inCHRNB3missense
variantcarriersversus.non-carriers andCHRNA3missensevariant
carriers versus. non-carriers using a Wilcoxon Rank-Sum Test.
Linear regression and Wilcoxon Rank-Sum tests were used as
COGEND is a sample of unrelated cases and controls.
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